Bristol-myers Squibb Compnay

Ambarish K Singh

Purushotham Vemishetti

Yadagiri R Pendri

Maotang X Zhou

Siva Josyula Prasad

Xinhua Qian

Ulhas P Dhokte

Emily A Reiff

Helen Sailes

Pia Mountford

Kerry B Hartung

John K Thottathil

Richard P Polniaszek

Gerald L Powers

Ramesh N Patel

Philip Michael Sher

David R Kronenthal

David J Kucera

John J Venit

Milan N Stojanovic

Victor W Rosso

Chung-Pin H Chen

Amit Banerjee

Jeffrey M Evans

John Anthony Grosso

Shaopeng Wang

Edward J Delaney

Zhongping Shi

Xuebao Wang

Shankar Swaminathan

Jeffrey T Bien

Jing Liang

Sunil S Patel

Wen-sen Li

Chien-Kuang Chen

Raymond E Weaver

Sushil K Rijhwani

Yeung Yu Chan

Dhileepkumar Krishnamurty

Charles Lewis

Yeung Y Chan

Milan Stojanovic

Processes for preparing entecavir and novel intermediates thereof using carbon-silicon oxidation. 

Intermediates in the preparation of entecavir via carbon-silicon oxidation

Process for preparation of entecavir and novel intermediates thereof via carbon-silicon oxidation

Process for the preparation of entecavir and novel intermediates thereof via carbon-silicon oxidation

Processes are disclosed for preparing the antiviral agent entecavir. A resin adsorption process for the isolation and purification of entecavir is also disclosed. Various intermediates useful in the preparation of entecavir are also disclosed.

Process for preparing the antiviral agent [1S-(1alpha,3 alpha,4beta )]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one

Methods for the preparation of biphenyl isoxazole sulfonamides and intermediates therof. The present invention also relates to the novel intermediates prepared by these methods. The biphenyl isoxazole sulfonamides prepared by the present methods are endothelin antagonists useful, inter alia, for the treatment of hypertension, congestive heart failure and male erectile dysfunction.

Methods for the preparation of biphenyl isoxazole sulfonamides

Novel reaction conditions for the cleavage of silyl ethers from silyl protected taxane precursors to afford paclitaxel and paclitaxel analogues in high yield and quality are described. Paclitaxel is prepared from a taxane precursor by treating the taxane precursor with a strong acid such as trifluoroacetic acid in a solvent such as aqueous acetic acid, such that the amount and number of side reactions and taxane impurities are significantly minimized. Also desribed are the crystallization methods for the isolation of paclitaxel in either of the two crystal forms A or B. Paclitaxel and paclitaxel analogues are anti-cancer agents.

Reaction conditions for the cleavage of silyl ethers in the preparation of paclitaxel(taxol&reg;) and paclitaxel analogues

A method is provided for preparing intermediates for 7-oxabicycloheptane carboxylic acid intermediates of the structures ##STR1## wherein R is alkyl, aryl, arylalkyl or cycloalkyl; R.sup.1 is alkyl, arylalkyl or cycloalkyl; R.sup.2 is aryl or arylalkyl; and of the structure ##STR2## where R and R.sup.1 are as defined above, which may be used in making the final anti-thrombotic--anti-vasospastic compounds.

7-oxabicycloheptane carboxylic acid prostaglandin analog intermediates

Growing community of inventors

Plainsboro, NJ, United States of America

Ambarish K Singh